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Purpose: Each year in France, varicella and zoster
affect large numbers of children and adults, resulting
in medical visits, hospitalizations for varicella- and
zoster-related complications, and societal costs. Dis-
ease prevention by varicella vaccination is feasible,
wherein a plausible option involves replacing the
combined measles, mumps, and rubella (MMR) vac-
cine with the combined MMR and varicella (MMRV)
vaccine. This study aimed to: (1) assess the cost-
effectiveness of adding routine varicella vaccination
through MMRV, using different vaccination strategies
in France; and (2) address key uncertainties, such as
the economic consequences of breakthrough varicella
cases, the waning of vaccine-conferred protection,
vaccination coverage, and indirect costs.
Methods: Based on the outputs of a dynamic
transmission model that used data on epidemiology
and costs from France, a cost-effectiveness model was
built. A conservative approach was taken regarding
the impact of varicella vaccination on zoster incidence
by assuming the validity of the hypothesis of an age-
speciﬁc boosting of immunity against varicella.
Findings: The model determined that routine MMRV
vaccination is expected to be a cost-effective option,
considering a cost-effectiveness threshold of €20,000 per
quality-adjusted life-year saved; routine vaccination was
cost-saving from the societal perspective. Results were*Current afﬁliation: Littlewood Writing Solutions, Houten, the
Netherlands.
†Current afﬁliation: Abbott Healthcare Products B.V., Weesp,
the Netherlands.
830driven by a large decrease in varicella incidence despite a
temporary initial increase in the number of zoster cases
due to the assumption of exogenous boosting. In the
scenario analyses, despite moderate changes in assump-
tions about incidence and costs, varicella vaccination
remained a cost-effective option for France.
Implications: Routine vaccination with MMRV
was associated with high gains in quality-adjusted
life-years, substantial reduction in the occurrences of
varicella- and zoster-related complications, and few
deaths due to varicella. Routine MMRV vaccination
is also expected to provide reductions in costs related
to hospitalizations, medication use, and general-
practitioner visits, as well as indirect costs, and it is
expected to be a cost-effective intervention in France
(GSK study identiﬁer: HO-12-6924). (Clin Ther.
2015;37:830–841) & 2015 The Authors. Published
by Elsevier HS Journals, Inc.
Key words: dynamic model, economic analysis,
France, vaccination, varicella, zoster.
INTRODUCTION
Varicella is a mild disease that affects a majority of the
worldwide population primarily during childhood.
The risk for varicella-related complications (eg, pneu-
monia, encephalitis, secondary bacterial infections)Accepted for publication January 16, 2015.
http://dx.doi.org/10.1016/j.clinthera.2015.01.006
0149-2918/$ - see front matter
& 2015 The Authors. Published by Elsevier HS Journals, Inc. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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K.J. Littlewood et al.and hospitalization increase with age and are notably
high in certain population subgroups, such as immu-
nocompromised individuals and neonates. After pri-
mary exposure, the varicella-zoster virus remains
latent in the dorsal root ganglia and can reactivate
later in life to cause herpes zoster in adults. Herpes
zoster disease is most common in people aged Z50
years and has been associated with long-term compli-
cations and pain.1
In 2010, a total of 766,000 cases of varicella (94% in
children aged r10 years)2 were reported in France, in
which there were 1,500 hospitalizations (data on ﬁle,
PMSI database, 2006) and 20 deaths4 (70% of deaths
were in individuals aged Z15 years5). As most children
are affected by varicella at a young age (median age, 3
years2), a large cost to society results from parents losing
workdays to care for their sick children. In France, there
were 270,000 cases of herpes zoster (68% in
individuals aged Z50 years),2 which were associated
with 2000 hospitalizations.3 Consequently, there are
signiﬁcant unmet clinical and economic needs for
preventing varicella and zoster diseases and complications.
Since 1974, a varicella vaccine based on the attenu-
atedOkavirus strain has been available. This vaccine has
been reported in clinical trials not only to be efﬁcacious
in protecting against varicella disease but also to have a
signiﬁcantly a lower reactivation rate than wild-type
virus, thus leading to a reduced risk for herpes zoster
in vaccinated populations.6,7 This varicella vaccine is
now available in combination with the measles, mumps,
and rubella (MMR) vaccine that is a part of universal
childhood immunization programs in most European
countries, wherein the MMR vaccine is typically given at
1 year of age, with a second dose given between 1 and 5
years of age. The World Health Organization recom-
mends the use of varicella vaccination in countries in
which a high coverage rate can be achieved and sustained
(ie, industrialized countries with temperate climates).8
Thus, replacing MMR with the combined MMR and
varicella (MMRV) vaccine will help to achieve high and
sustained coverage of varicella vaccination.
Routine varicella vaccination has been successfully
used in the United States since 1995, resulting in
signiﬁcant cost-savings to US society. Hospitalization
costs declined from an estimated $161.1 million in 1993
to $66.3 million in 2001 after widespread immuniza-
tion9 due to the direct impact of varicella vaccination
(fewer hospitalizations and doctor visits) and
diminished indirect costs due to reduced productivityApril 2015losses.10 Varicella vaccination is still uncommon in
most European countries, including France, and tends
to be included only in targeted vaccination programs
for high-risk groups.11 Although routine vaccination
is expected to signiﬁcantly reduce the incidence of
varicella and, in the long term, zoster disease burden,
in vaccinated individuals12 it may also provide indirect
consequences, such as delaying the age of infection
through reduced exposure to the virus. However,
varicella infection at an older age has been associated
with more severe disease (eg, a greater incidence of
complications and hospitalizations and increased health
care resource utilization).10,11,13 Moreover, as vaccina-
tion is not 100% efﬁcacious in all patients, there may be
a few partial responders, with a small fraction of
complete failures, resulting in mild or breakthrough
varicella despite vaccination. Mild and breakthrough
cases may affect the transmission of the virus and
consequently impose a burden on health care resource
utilization and costs.
To better understand the impact of all of these
factors, the present study aimed to: (1) assess the cost-
effectiveness of adding routine varicella vaccination
through MMRV, using different vaccination strat-
egies, in France; and (2) address key uncertainties,
such as the economic consequences of breakthrough
varicella cases, the waning of vaccine-conferred pro-
tection, vaccination coverage, and indirect costs.
MATERIALS AND METHODS
Model Overview
The impact of routine varicella vaccination was
assessed by using an age-structured dynamic trans-
mission model to predict the incidence of varicella and
herpes zoster disease. The dynamic model was devel-
oped after a thorough review of existing models,13–15 so
that it can be considered to present the disease in the
most realistic way possible (ie, including important
features such as maternal antibody protection, impact
on zoster disease, age structures, and exogenous boost-
ing effects16,17). In this analysis, we used an empirically
based contact matrix, whereas previous models of
varicella have had to rely on assumptions about
interactions between individuals that result in the spread
of infection. The model was built using French demo-
graphic and epidemiologic data. Details of the dynamic
model, the impact of the contact matrix, and exogenous
boosting on varicella and zoster disease epidemiology
have been reported separately by Ouwens et al.18831
Clinical TherapeuticsIn this cost-effectiveness analysis, we considered
both the payer and societal perspectives. Epidemiol-
ogy outputs from the published dynamic model19 and
data on economic burden were used to populate the
model. French data on age-speciﬁc health care re-
source utilization, costs, and rates of complications
and deaths were applied to each type of case. The
comparisons of interventions included MMRV vacci-
nation versus the standard of care (ie, MMR vacci-
nation [versus no varicella vaccination]). No
comparison was made with regard to the individual
MMR components of the vaccines as this comparison
was not relevant to the study of varicella prevention.
The model considered a time horizon of 80 years to
represent a lifetime period. The main outcomes of
interest were direct and total cost per quality-adjusted
life-year (QALY) saved and cases and complications
avoided over time.
Model Inputs and Assumptions
The model inputs used for calculating age-speciﬁc
QALYs, complications, and deaths due to varicella
and zoster in France are provided (see Supplemental
Tables I–III in the online version at http://dx.doi.org/
10.1016/j.clinthera.2015.01.006). Complications of
varicella occur most frequently in infants o1 year of
age (6.29%) and in adults Z20 years of age (8.81%).
As most varicella cases currently do not occur in these
2 age groups, an increase in the incidence of varicella
in these age groups (ie, age shift) could potentially
increase the burden of the disease.
The direct costs associated with the disease and its
treatment included the costs of general-practitioner
(GP) and outpatient visits, medication, hospitalization,
and vaccines. In France, data from sentinel surveil-
lance2 suggest that 96% of patients see a GP for the
treatment of varicella; therefore, vaccination has the
potential to signiﬁcantly reduce health care resource
utilization and health care costs. Indirect costs assessed
included workdays lost in patients with varicella and
in parents of children with varicella, in addition to
costs of alternative child care arrangements (see
Supplemental Tables IV and V in the online version
at http://dx.doi.org/10.1016/j.clinthera.2015.01.006).
In France, an estimated 30% of parents lose work-
days or pay a caregiver to care for children with
varicella, resulting in a large indirect societal costs.20
Although individuals who have been vaccinated
may still develop varicella (breakthrough varicella), it832has been observed that breakthrough varicella cases
are typically mild and occur less frequently in patients
who have received the full 2-dose schedule of
varicella vaccination.21 For instance, based on data
from sentinel surveillance in Germany, where routine
varicella vaccination was introduced in 2004, the
estimated incidence of breakthrough cases 2 years
after the start of vaccination was 1.8 per 1000
individuals vaccinated with 1 dose compared with
0.4 per 1000 individuals vaccinated with 2 doses.21
The model assumed that the rates of hospitalization
and death related to breakthrough varicella were
1.0% of those observed with wild-type varicella,22
and given the lack of current data, the same
assumption was made for herpes zoster. Similarly,
the percentage of mild varicella and zoster cases that
incur indirect costs was assumed to be 1.0% of those
observed with wild-type varicella.
Base-Case Analyses: French Current Coverage
and Optimal Coverage Scenarios
The base-case scenario (French current coverage)
uses the current MMR coverage levels in France
(dose 1, 90%; dose 2, 80%) and assumes a gradual
replacement by MMRV of up to 80% within 3 years.
As higher MMR vaccination coverage is reached in
many other European countries, an optimal vaccina-
tion coverage scenario was also analyzed. In the
optimal coverage base-case analysis, the following
assumptions were used. The ﬁrst dose of MMR is
given at 12 months of age (with a coverage of 95%),
and a second dose, at 18 months of age (with a
coverage of 90%). MMRV will gradually replace
MMR in 100% of vaccinated children within 3 years.
The efﬁcacy of 2 doses of vaccine will be 95%, with a
duration of protection of 17 years after the admin-
istration of the ﬁrst dose, increasing to lifelong
protection after the administration of the second dose
among those successfully vaccinated (ie, fully pro-
tected). As in other varicella models, response to the
vaccine includes full protection, partial protection,
and failures. A varicella vaccine “catch-up” program
was implemented in children aged 10 years, with a
coverage of 50%. The catch-up program is assumed
to run from the start of vaccination to 8 years (ie, until
the original vaccination cohort reached the catch-up
age group). Taking a conservative approach, natural
age-speciﬁc immunity boosting was assumed, as was
an adverse impact on zoster cases after vaccination,Volume 37 Number 4
French coverageA
B
14
12
10
8
6
4
2
0
0–10 10 20 30
Time (years)
Va
ric
el
la
 in
ci
de
nc
e
(p
er
 1
00
0 
pe
rs
on
-y
ea
rs
)
40 50 60 70 80
Current
Rapid replacement
Extended interval
Base-case
Optimal coverage
14
12
10
8
6
4
2
0
0–10 10 20 30
Time (years)
Va
ric
el
la
 in
ci
de
nc
e
(p
er
 1
00
0 
pe
rs
on
-y
ea
rs
)
40 50 60 70 80
Current
Rapid replacement
Extended interval
Base-case
Figure 1. Varicella incidence over time with
French coverage (A) and optimal
coverage (B).
K.J. Littlewood et al.causing an increase in cases among nonvaccinated
individuals in the intermediate term (ie, until the
vaccinated cohort reaches the age at which zoster is
a risk).
The efﬁcacy data were based on ﬁndings from a
multicenter, randomized, observer-blinded, controlled
study in 10 European countries (N ¼ 5803). The
vaccine efﬁcacy of 2 doses of MMRV against any
varicella was 94.9% (97.5% CI, 92.4%–96.6%) and
against moderate or severe varicella was 99.5% (97.5%
CI, 97.5%–99.9%) at a mean follow-up of 35 months
after the administration of the second dose.23 The
duration of protection after 1 dose of MMRV (ie, 17
years) was estimated by ﬁtting a curve to observational
effectiveness data over 6 years using data from a large
health maintenance organization in Israel (N ¼
180,139), where a 1-dose varicella vaccination schedule
was introduced in 2000.24 The duration of protection
was assumed to be lifelong (expert consultation) after
the administration of 2 doses of MMRV. Support for
this assumption may be provided by ﬁndings from a 10-
year follow-up study that reported that protection is an
estimated 3-fold greater with 2 doses of varicella
vaccine versus 1 dose.25
Scenario and Sensitivity Analyses
Scenario analyses were carried out to test the
impact of different vaccination strategies and assump-
tions; for example, the impact of a rapid replacement
strategy (eg, achieving full coverage within 1 year
instead of 3 years), using an extended dosing interval
of 4 years, discounting costs (at 4% until 30 years
after start of vaccination, 2% from 30 years after start
of vaccination) but not beneﬁts (discounted at 4% in
the base-case until 30 years after the start of vacci-
nation; 2% from 30 years after the start of vaccina-
tion), and including indirect costs to assess the societal
perspective. A scenario was run using the assumption
that breakthrough cases are not different from natural
varicella and zoster cases in terms of the risks for
complications, hospitalizations, and deaths and the
indirect costs incurred. A scenario assessed the impact
of different assumptions about the waning of vaccine
efﬁcacy (ie, 10 years of protection instead of 17 years
after the ﬁrst dose, and 30 years instead of lifelong
protection after the second dose). A probabilistic
sensitivity analysis was used to obtain 95% CIs
around the cost-effectiveness results in the economic
model (for the parameters that were varied andApril 2015distributions used, see Supplemental Table VI in the
online version at http://dx.doi.org/10.1016/j.clinthera.
2015.01.006). The epidemiologic data used in the
economic model were obtained from the dynamic
model, in which several scenario analyses were run
in place of a probabilistic sensitivity analysis to assess
uncertainty.
RESULTS
Cases of Varicella and Zoster Averted
Figure 1 shows the impact of varicella vaccination
on the incidence of varicella with A) French
coverage and B) Optimal coverage and with the
following dosing scenarios; ‘Current’ (ie, only MMR
vaccination), ‘Rapid replacement’ and ‘Extended
interval’. After varicella vaccination implementation,
at 30 years, the incidence of varicella disease is
expected to be reduced to 4.0 per 1000 person-years833
Clinical Therapeutics(a reduction of 69%) in the French current coverage
scenario and to 0.4 per 1000 person-years (a reduc-
tion of 97%) in the optimal coverage scenario com-
pared with 12.7 per 1000 person-years before
varicella vaccination. With the exogenous boosting
assumption, the incidence of zoster is expected to
increase after vaccination but then to decline to levels
lower than current levels at 19 years after the start of
vaccination. As routine MMR vaccination with a high
coverage has been shown26 to induce a herd
protection effect, routine infant vaccination had an
impact on the incidence of varicella in all age groups.
Detailed epidemiologic results of the model were
presented by Ouwens et al.18
In the rapid replacement scenario, the number of
varicella cases is expected to decline at a faster rate
compared with that in the base-case analysis. In the
extended dosing interval scenario, the number of
varicella cases is expected to be higher than the French
current coverage but is comparable to the Optimal
coverage.Deaths Avoided and QALYs Gained
Deaths and QALYs lost for both varicella and
zoster are projected to decrease after varicella vacci-
nation, as fewer cases of varicella are shown to occur
(See Figure 1) and due to the assumption that
breakthrough cases are milder than are natural cases
of varicella. Death due to varicella is relatively
uncommon (ie, 12 deaths/y [range, 5–25] in
France, or 0.002% of varicella cases). With zoster,
death is more common, especially among older age
groups (eg, 0.04% of zoster cases in individuals aged
Z65 years). As the base-case conservatively assumes
that the exogenous boosting hypothesis is valid,
vaccination is expected to cause a temporary
increase in the incidence of zoster; the model is
expected to reach a maximum of 0.063 additional
zoster deaths per 1 million population per year at 25
years after the start of vaccination (when the incidence
of zoster in the Z65-year age group is highest),
whereas 0.25 varicella-related deaths are avoided in
the optimal coverage scenario. In the French current
coverage scenario, the model is expected to reach a
lower maximum of 0.045 additional zoster deaths per
1 million population per year at 18 years after the
start of vaccination, whereas 0.19 varicella-related
deaths would be avoided for the same year. Overall,834deaths due to varicella and zoster are expected to be
reduced after routine varicella vaccination.
The utility values used in the model assumed that
quality of life was worse in zoster compared with
varicella, in older versus younger age groups, and in
cases with complications compared with cases without
complications. Before varicella vaccination, the QALY
loss associated with varicella is expected to be 52 per
1 million population per year, and with zoster, 133
per 1 million population per year. After MMRV
introduction, the QALY loss associated with varicella
is shown to decline to 15 per 1 million population
per year (by year 20) in the French current coverage
scenario and to 1 per 1 million population per year
(by year 14) in the optimal coverage scenario. In the
French current coverage scenario, QALY loss associ-
ated with zoster peaked at 139 per 1 million popula-
tion per year around 17 years after the start of
vaccination due to the estimated increase in zoster
cases, followed by a gradual decline. QALY loss
associated with zoster was 116 per 1 million
population per year when the original vaccinated
cohort reached 60 years of age and declined to 60
per 1 million population per year 20 years later. For
the optimal coverage assumption, QALY loss associ-
ated with zoster peaked at 141 per 1 million popula-
tion per year 20 years after the start of vaccination
due to the estimated increase in zoster cases and then
declined to 25 years after vaccination was started.
QALY loss associated with zoster was 108 per 1
million population per year when the original vacci-
nated cohort reached 60 years of age and declined to
33 per 1 million population per year 20 years later.
Overall, in varicella and zoster combined, the intro-
duction of MMRV provided savings in QALYs
compared with no varicella vaccination (Figure 2).
Direct and Indirect Costs of Each Intervention
Varicella is frequently associated with GP and
outpatient costs in France because 96% of patients
visit a GP for a varicella infection regardless of
complications (estimate based on Sentiweb data2).
Additional examination and medication may be
prescribed in older patients who are considered at
greater risk for complications. Hospitalization rates
are generally low in varicella, except in elderly
patients; however, total costs of hospitalizations may
be high due to the large prevalence of the disease.
Therefore, reducing the number of varicella cases inVolume 37 Number 4
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Figure 3. Breakdown of direct and indirect costs
per 1 million population per year with
measles, mumps, rubella, varicella vac-
cination with French coverage (A) and
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varicella vaccination (versus no var-
icella vaccination) (undiscounted).
K.J. Littlewood et al.any age group will have an impact on the direct costs
to the health service provider.
Vaccination costs increased in the ﬁrst 3 years as
MMRV coverage increased (Figure 3). All direct costs
decreased after MMRV vaccination versus the current
situation of no varicella vaccination, except for
vaccine costs due to the higher price of the MMRV
compared with the MMR vaccine. The variations in
incidence in the ﬁrst few years after vaccination
explain the observed variations in costs. The data at
15 years post introduction of MMRV are shown for
comparing expected costs once varicella incidence is
near its new, stabilized, lower value.
The indirect costs measured included costs due to
lost productivity in adult patients with varicella or
zoster and lost workdays in parents of pediatric
patients. Based on ﬁndings from a study from France,
it was assumed that 17% of parents lost 5 workdays,
and that 13% of parents of children with varicella
paid for alternative child care.19 Given the high
prevalence of varicella among children, the indirect
costs due to the disease are substantial.
The use of MMRV was associated with a decrease
in indirect costs due to varicella and zoster compared
with the current situation, driven by the decrease in
varicella cases. Indirect costs per year were estimated
at €7.2 million in France before MMRV vaccination
compared with €4.9 million with the French currentApril 2015coverage and €4.8 million with the optimal coverage
15 years after the start of vaccination.
Cost-Effectiveness Results
Routine MMRV vaccination is projected to signiﬁ-
cantly reduce the incidence of varicella and its com-
plications and the incidence of zoster in the long term,
resulting in QALYs saved. These outcomes are835
Table I. Cumulative varicella cases avoided, QALYs saved, and cost differences (“€”) per 1 million population
per year with MMRV (versus no varicella vaccination).
Parameter
French Coverage Optimal Coverage
MMRV,
Year 1
MMRV,
Year 5*
MMRV,
Year 15
MMRV,
Year 1
MMRV,
Year 5*
MMRV,
Year 15
Varicella cases avoided 4064 35,205 134,154 5027 39,036 156,767
QALYs saved 16.59 126.52 377.63 20.50 140.18 431.07
Direct cost difference, € 76,131 1,174,142 3,100,764 111,943 1,921,815 5,088,393
Total cost difference, € 879,351 6,111,157 17,888,700 1,067,696 6,143,941 19,291,732
Direct cost per QALY
(cumulative values), €
4588 9280 8211 5460 13,709 11804
Direct cost per QALY,
(yearly values), €
4588 49,781 19,780 5460 74,319 24,442
MMRV, measles, mumps, rubella, varicella; QALYs, quality-adjusted life-years.
*Due to so-called post-honeymoon peak in cases e.g. at year 5 (see Figure 1).
Clinical Therapeuticspresented in Table I, with costs and QALYs
discounted at 4% per year after the ﬁrst year. The
total cost difference includes the indirect costs saved
by MMRV vaccination and is negative, indicating an
overall cost-saving scenario. In the French current
coverage scenario, the direct cost per avoided compli-
cation was €483, and per avoided varicella case was
€23 at 15 years after the start of vaccination. In the
optimal coverage scenario, the direct cost per avoided
complication was €702, and per avoided varicella case
was €32 at 15 years after the start of vaccination.
From the payer’s perspective, with costs and QA-
LYs discounted at 4% per year until 30 years after the
start of vaccination and 2% per year from 30 years
after the start of vaccination, the costs per QALY
saved at 15 years after the start of vaccination were
€8211 (95% CI, 2053–26,168) in the French current
coverage scenario and €11,804 (95% CI, 4711–
38,605) in the optimal coverage scenario. From a
societal perspective, including direct and indirect
costs, routine MMRV vaccination provided more
beneﬁts at a lower cost and was therefore the
dominant strategy versus no varicella vaccination in
both the French current coverage and the optimal
coverage scenarios. When only costs were discounted,
the direct cost per QALY in year 15 postvaccination
decreased from €8211 to €6237 in the French current
coverage scenario and from €11,804 to €8926 in the
optimal coverage scenario.836The strategies remained dominant from a societal
perspective. Figure 4 shows the incremental cost-
effectiveness ratios over time with MMRV versus no
varicella vaccination (cost-effectiveness plane) and the
corresponding cost-effectiveness acceptability curves,
using a willingness-to-pay threshold of €20,000 per
QALY saved.
At a willingness-to-pay threshold of €20,000 per
QALY saved, there is a high probability that MMRV
vaccination will be cost-effective (ie,490% at all time
points in the French current coverage scenario and
70% at year 5 in the optimal coverage scenario, with
490% at other time points with optimal coverage).
Indirect costs were signiﬁcantly lower with MMRV
compared with MMR (ie, no varicella vaccination),
and as a result the total costs were lower in the
MMRV arm versus the no varicella vaccine arm in
both the French current coverage and the optimal
coverage scenarios. Therefore, the beneﬁts of vacci-
nation could be achieved with cost-savings. The
probability of MMRV being cost-effective was
therefore 100%.
In the rapid replacement scenario, wherein the
MMRV strategy allows more varicella cases to be
prevented and at a faster rate than in the base-case
strategy, a rapid gain in clinical beneﬁts, accompanied
by a substantial reduction in health care and indirect
costs, was estimated. The costs of vaccination in the
rapid replacement scenario were, however, higher inVolume 37 Number 4
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Figure 4. Cost-effectiveness planes (A and B) and acceptability curves (C and D) (direct costs, willingness
to pay at €20,000 per quality-adjusted life-year [QALY]) with French coverage and optimal
coverage.
K.J. Littlewood et al.the ﬁrst few years, as it was assumed that MMRV
would replace all MMR within 1 year instead of 3
years (base-case). Using the French coverage and rapid
replacement dosing scenario results in a direct cost of
€488 per complication avoided and €23 per varicella
case avoided, at 15 years after the start of vaccination.
Using the Optimal coverage and rapid replacement
scenario, the direct costs are €713 and €33 per
complication avoided and varicella case avoided
respectively. Despite a high incremental cost-
effectiveness ratio estimate, the probability of MMRV
being cost-effective was high (460%, depending on
time since vaccination introduced for optimal cover-
age, and 480% with the French current coverage) at
a willingness-to-pay threshold of €20,000/QALY
gained.
In the scenario with a 4-year dosing interval, the
vaccine costs were lower than those in the base-case
for the ﬁrst 4 years, and during this period, vaccine
efﬁcacy was relatively comparable. This ﬁnding is
explained by the high coverage and efﬁcacy with the
ﬁrst dose and the minor impact due to waning of
protection in this period. Thus, the direct cost perApril 2015QALY is expected to be lower than that observed in
the base-case.
The impact of having a lower coverage with the
second dose of the vaccine, or of having a shorter
duration of protection (ie, faster waning of vaccine
efﬁcacy), was to provide less protection against vari-
cella. Under the assumption of exogenous immunity
boosting, the high number of circulating varicella
cases provides improved protection against zoster;
therefore, the increase in zoster incidence after vacci-
nation was lower in these scenarios compared with
that in the base-case. The impact on cost-effectiveness
is presented in Table II.
All scenarios were cost-effective, with incremental
cost-effectiveness ratio estimates below the threshold
of €20,000/QALY gained. As the number of deaths
due to varicella-zoster virus in nonvaccinated patients
is o1 per 1 million population per year, the number
of deaths that could be averted is very low. As
a consequence, the cost per life year gained is
high. Table II compares outcomes with the French
coverage versus Optimal coverage for different dosing
scenarios. The French coverage results are better in the837
Table II. Direct cost per QALY saved and cost per death avoided with MMRV (versus no varicella
vaccination). Data are given as € (2010).
Parameter
French Coverage Optimal Coverage
Base
Case
Rapid
Replacement
Longer
Dose
Interval
Shorter
Protection
Base
Case
Rapid
Replacement
Longer
Dose
Interval
Shorter
Protection
Cost per QALY
saved
Year 5 9280 10,744 1542 9551 13,709 15,340 3448 9640
Year 15 8211 8148 5357 9171 11,804 11,817 8072 7989
Cost per death
avoided
Year 5 1,733,765 2,032,046 285,750 1,782,472 2,572,219 2,897,927 641,842 1,803,675
Year 15 1,285,163 1,297,777 832,301 1,427,166 1,849,976 1,878,544 1,258,765 1,247,346
QALY, quality-adjusted life-year.
Clinical Therapeuticsbase-case, rapid replacement (ie, 2nd dose shortly
after 1st dose) and longer dose interval scenarios.
However, the Optimal coverage results are better in
the Shorter protection duration scenario.
A scenario analysis assessed the cost-effectiveness
of varicella vaccination by varying the price of
MMRV (€54/dose) within 10%. At a lower price
of MMRV (€48.60/dose), the direct costs per QALY
gained were €5995 and €8672 at 15 years after the
start of vaccination in the French coverage and
optimal coverage scenarios, respectively. At a higher
price of MMRV (€59.40/dose), the direct costs per
QALY gained were €10,827 and €14,397 at 15 years
after the start of vaccination in the French coverage
and optimal coverage scenarios.
DISCUSSION
To date, in considering the risk–beneﬁt proﬁle of
implementing routine varicella vaccination, there has
been uncertainty as to whether vaccination might
increase the disease burden of varicella (by causing
an age shift from children and adolescents to older age
groups27) and zoster (by increasing the number of
cases temporarily27 if exogenous boosting plays a
role). In view of these potential increases in disease
burden, the alternative to routine vaccination (ie,
targeted varicella vaccination in adolescents) has
been implemented in several European countries.838However, this strategy offers no control of the
disease and does not beneﬁt the broader population
as there is no herd protection conferred from targeted
vaccination. In addition, as most cases occur in
childhood, there is a large burden on families, large
indirect costs incurred, and a large ﬁnancial burden to
health care systems.
This model differs from previous models because it
uses empirically derived contacts rather than hypo-
thetical ones (see Ouwens et al18). The presence and
impact of exogenous natural immunity boosting are
much debated in the literature, with no conclusive
evidence available.28 As routine MMRV vaccination
has been implemented in the US and Germany for a
considerable time, conclusive evidence may come from
sentinel data on zoster incidence in the next few years.
This analysis assumes that age-speciﬁc partial exoge-
nous immunity boosting does exist15 and therefore a
small temporary increase in zoster cases was observed.
The more recent exogenous partial boosting
assumption results in a lower vaccine impact on
zoster cases and improved cost-effectiveness ratios.
Despite the short-term increase in zoster cases, routine
varicella vaccination is expected to reduce the overall
burden and costs on health care systems and society
overall. Given a willingness-to-pay threshold of
€20,000/QALY saved, MMRV vaccination is ex-
pected to be a cost-effective option in France and aVolume 37 Number 4
K.J. Littlewood et al.cost-saving option when considering total costs
averted.
Merits of this analysis include the use of an age-
structured model based on disease transmission dy-
namics, with empirically derived contacts and robust
vaccine efﬁcacy estimates from clinical-trial data.
Several scenario analyses were carried out to assess
uncertainty in the dynamic model as it was not
possible to carry out a probabilistic sensitivity analysis
due to a lack of data. Although static models have
been used in the past, they are less appropriate as they
cannot capture the indirect effects such as herd effect,
waning immunity, and age-speciﬁc contact patterns
within populations on the epidemiology of infectious
diseases and thus on cost-effectiveness.12–14
The main limitations of this economic analysis were
the lack of relevant and up-to-date French utility data
and the uncertainty surrounding the long-term efﬁcacy
and impact of the vaccine on zoster. Utility data were
therefore taken from 2 studies1,29 that considered age
groups, complications, and varicella and zoster. A
recent study that assessed utility loss in children aged
o3 years with varicella in Belgium reported that
utility-loss values were higher in those seeking GP
care compared with those in children who did not see
a GP and were highest in hospitalized children. In
addition, utility-loss values were assumed to be higher
in adults than in children.30 The model values used
were comparable to those in children not seeking GP
care and therefore may have underestimated the
burden of varicella. The model assumed that
breakthrough cases would result in mild varicella
and zoster disease from partially protected vaccine
recipients but not from complete vaccine failures.
Observational data from countries where routine
MMRV vaccination is implemented suggest that
breakthrough cases are mild; however, a scenario
testing this assumption and its implications on
complication rates revealed that the reductions in
complications and disease burden were important in
that the beneﬁts of MMRV vaccination outweigh the
impact of any breakthrough-case assumptions. The
use of shorter estimates of vaccine waning and a lower
vaccination coverage rate with the second dose of the
vaccine was associated with less protection against
varicella, which, in turn, was associated with less of an
increase in the number of zoster cases in the short
term and a higher zoster incidence compared with the
base-case in the long term. Despite these assumptions,April 2015MMRV vaccination had a signiﬁcant overall effect on
controlling the disease and remained a cost-effective
option for the prevention of varicella in France.
CONCLUSIONS
A varicella vaccine that can be given at sufﬁcient
vaccination coverage levels to meet the criteria of the
World Health Organization is available. In this dynamic
model for France, routine varicella vaccination signiﬁ-
cantly reduces the incidence of the disease. Furthermore,
the cost-effectiveness analysis for France suggests that
routine MMRV vaccination is expected to provide more
QALYs gained, fewer complications, and fewer deaths
in the long term compared with MMR (no varicella
vaccination), as well as provide signiﬁcant savings in
direct and indirect costs. The scenario analyses suggest
that an optimized vaccination strategy aimed at achiev-
ing higher coverage in a short span of time may improve
the impact of the routine MMRV vaccination program
while remaining within cost-effectiveness thresholds.
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Clinical TherapeuticsModel Input Data, Variables, and distributions.Supplemental Table I. QALY loss among varicella and zoster cases, by age.*
Virus Natural Mild
No varicella or zoster (all ages)† 0 (All ages)
Varicella‡
Age 0–o15 y 0.004 0.001
Age Z15 y 0.005 0.001
Herpes zoster§
No PHN
Age 0–o60 y 0.010 0.010
Age 60–o65 y 0.010 0.010
Age Z65 y 0.011 0.011
PHN
Age 0–o60 y 0.011 0.098
Age 60–o65 y 0.106 0.098
Age Z65 y 0.144 0.093
PHN, postherpetic neuralgia; QALY, quality-adjusted life-years.
*The percentage of varicella cases with any complication by age group in France was reported in Coudeville L, Brunot A,
Szucs TD, Dervaux B. The economic value of childhood varicella vaccination in France and Germany. Value in Health.
2005;8:209-222. The breakdown by type of complication in 2002 was reported in Bonmarin I, Ndiaye B, Seringe E, Levy-
Bruhl D. Épidémiologie de la varicelle en France [in French]. Bull Epidemiol Hebd. 2005;8:30. By combining both sets of
data, we obtained an estimate of the age-speciﬁc distribution by type of complication. This method assumed that all
complications were equally likely to occur in each age group (Table II).
†Assumption.
‡Brisson M, Edmunds WJ. Varicella vaccination in England and Wales: cost-utility analysis. Arch Dis Child. 2003;88:862-869.
§Data from Pellissier JM, Brisson M, Levin MJ. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent
herpes zoster and postherpetic neuralgia in older adults. Vaccine. 2007;25:8326-8337.841.e1 Volume 37 Number 4
Supplemental Table II. Complications among varicella and zoster cases, by age.* Data are presented as %
of cases.
Virus/Age, y Cutaneous Neurologic Pulmonary Ocular PHN Other Total
Varicella†
0–o1 1.55 0.60 1.08 – – 3.06 6.29
1–o5 1.17 0.45 0.82 – – 2.31 4.75
5–o10 0.85 0.33 0.59 – – 1.68 3.45
10–o15 0.87 0.34 0.61 – – 1.71 3.52
15–o20 0.58 0.23 0.41 – – 1.15 2.37
Z20 2.17 0.84 1.52 – – 4.29 8.81
Zoster
0–o60‡ – 0 – 0 0 0 0
60–o65§ – 3.19 – 3.98 13.18 2.83 23.18
Z65 – 5.19 – 4.78 23.10 5.74 38.81
PHN, postherpetic neuralgia; QALY, quality-adjusted life-years.
*The model assumed that zoster cases aged 0 to o60 years were uncomplicated and that breakthrough zoster cases had
complications with a rate of 1% of the rate in natural zoster cases. The number of deaths due to varicella were calculated at
12 (range, 5–25) per year in France, according to analyses of varicella deaths from 1979 to 2000, reported in Bonmarin I,
Ndiaye B, Seringe E, Levy-Bruhl D. Épidémiologie de la varicelle en France [in French]. Bull Epidemiol Hebd. 2005;8:30. In
2000, there were 630,000 varicella cases reported by Sentiweb; thus, a case fatality rate due to varicella of 0.002%
(range, 0.001%–0.004%). The case fatality rate due to zoster was estimated, based on data from the United Kingdom, in
Edmunds WJ, Brisson M, Rose JD. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in
England and Wales. Vaccine.2001;19:3076-3090. In patients aged o45 years, the number of deaths due to zoster was
assumed to have been negligible (Table III).
†Data from Coudeville L, Brunot A, Szucs TD, Dervaux B. The economic value of childhood varicella vaccination in France
and Germany. Value in Health. 2005;8:209-222; and Bonmarin I, Ndiaye B, Seringe E, Levy-Bruhl D. Épidémiologie de la
varicelle en France [in French]. Bull Epidemiol Hebd. 2005;8:30.
‡Assumption.
§Data from Pellissier JM, Brisson M, Levin MJ. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent
herpes zoster and postherpetic neuralgia in older adults. Vaccine. 2007;25:8326-8337.
Supplemental Table III. Death rate among zoster cases, by age.* Data are presented as % of cases.
Age, y
o45 45–o50 50–o55 55–o60 60–o65 Z65
Death rate 0 0.0011 0.0009 0.0009 0.0027 0.0403
*Based on data from Edmunds WJ, Brisson M, Rose JD. The epidemiology of herpes zoster and potential cost-effectiveness of
vaccination in England and Wales. Vaccine.2001;19:3076-3090.
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Supplemental Table IV. Costs, by health care resource, of varicella and zoster (inflated to year-2010 €).*
Resource Cost Description
GP/outpatient costs
(in cases of outpatient
care)
Varicella† €36 in patients aged o14 y;
€44 in patients aged414 y
Assumes that 96%–100% patients see a GP; includes
GP and home visits, medication, additional
examinations, and 7.7%–9.9% with complications.
Zoster‡ €98; €146 (þPHN); €154
(þ ophthalmic)
Assumes that 100% of patients see a GP; includes GP
visits, laboratory tests, medication and specialist
referrals for zoster and complications.
Hospital costs (in
hospitalized cases)§
Varicella €3,033 Includes weighted average of hospital costs,
including all complications.
Zoster €4,320 Includes weighted average of hospital costs,
including all complications.
Vaccination
MMR‖ €14.75 per dose –
MMRV‖ €54 per dose Two doses MMRV to replace 2 doses MMR.
Varicella‖ €41.24 per dose Monovalent varicella vaccine used for catch up
program.
AEs§,¶ €1,882 0.05% with febrile convulsions; hospital cost.
Indirect costs
Varicella,**
(all cases)
€154 in patients aged o18 y;
€1,311 in patients aged
Z18 y
Includes 73% of adults taking 10 days off, 17% of
parents taking 5 days off, and 13% of parents
paying alternative childcare (€73); daily cost €165/
workday lost.
Zoster**,††
(ages 18–65 y)
€2,121 Includes 80% of adults (aged 18–65 y) taking 16 days
off; daily cost €165/workday lost.
AE, adverse event; GP, general practitioner; MMR, measles, mumps, rubella; MMRV, measles, mumps, rubella, varicella;
PHN, post-herpetic neuralgia.
*To derive the age-speciﬁc hospitalization rates, the distributions of hospitalization, by age, in cases of varicella in France
(reported in Boelle PY, Hanslik T. Varicella in non-immune persons: incidence, hospitalization and mortality rates. Epidemiol
Infect. 2002;129:599-606) and in cases of zoster in Italy (reported in Di Legami V, Gianino MM, Atti MC, et al.
Epidemiology and costs of herpes zoster: background data to estimate the impact of vaccination. Vaccine.2007; 25:7598-
7604) were combined with total numbers hospitalised and incidence data from 2006 for France (Table V).
†Data from Boelle PY, Hanslik T. Varicella in non-immune persons: incidence, hospitalization and mortality rates. Epidemiol
Infect. 2002;129:599-606; Brisson M, Edmunds WJ. Varicella vaccination in England and Wales: cost-utility analysis. Arch
Dis Child. 2003;88:862-869; Emery C, Lançon F, Fagnani F, Pechevis M, Durand I, Floret D. ENVOL study on the medical
management of varicella and its complications in French ambulatory care. Méd Mal Infect. 2006; 36:92-98; Vidal Le
Dictionnaire 2008. http://www.vidal.fr. Accessed March 14, 2014; and L’assurance maladie. http://www.ameli.fr. Accessed
March 14, 2014.
‡Data from Brisson M, Edmunds WJ. Varicella vaccination in England and Wales: cost-utility analysis. Arch Dis Child.
2003;88:862-869; Chidiac C, Bruxelle J, Daures JP, Hoang-Xuan T et al. Characteristics of patients with herpes zoster on
presentation to practitioners in France. Clin Infect Dis. 2001;33:62-69; Vidal Le Dictionnaire 2008. http://www.vidal.fr.
Accessed March 14, 2014; and L’assurance maladie. http://www.ameli.fr. Accessed March 14, 2014.
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§Data from PMSI. Le programme de médicalisation des systèmes d’information en soins de courte durée. 2006. http://www.
atih.sante.fr. Accessed March 14, 2014.
‖Assumption.
¶Data from Klein NP, Yih WK, Marin M et al. Update: Recommendations from the Advisory Committee on Immunization
Practices (ACIP) regarding administration of combination MMRV vaccine. MMWR Morb Mortal Wkly Rep. 2008; 57:258-
260.
Data from Emery C, Lançon F, Fagnani F, Pechevis M, Durand I, Floret D. ENVOL study on the medical management of
varicella and its complications in French ambulatory care. Méd Mal Infect. 2006; 36:92-98.
**Data from Coudeville L, Brunot A, Szucs TD, Dervaux B. The economic value of childhood varicella vaccination in France
and Germany. Value in Health. 2005;8:209-222.
††Data from Pellissier JM, Brisson M, Levin MJ. Evaluation of the cost-effectiveness in the United States of a vaccine to
prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine. 2007;25:8326-8337.
Supplemental Table V. Hospitalization among varicella and zoster case, by age. Data are presented as %
of cases.
Virus
Age, y
0–o1 1–o5 5–o15 15–o25 25–o35 35–o45 45–o65 Z65
Varicella 1.61 0.11 0.07 0.33 0.67 0.90 3.21 3.79
Zoster 0.00 0.00 0.00 0.56 0.56 0.56 0.67 1.44
Supplemental Table VI. Parameters and distributions of probabilistic sensitivity analysis (PSA).
Parameters in the Model and Values With
Distribution for the PSA
Base
Case Low High
Uncertainty
distribution
Varicella cases, %
With visits to GP and outpatient care
Age 0–o15 y 96 95.2 96.8 Beta
Age 15–o65 y 96 95.2 96.8 Beta
Age Z65 y 100 100 100 Beta
Breakthrough cases with visits, relative to varicella 100 100 100 Beta
Zoster cases, %
With visits 100 100 100 Beta
Breakthrough cases with visits, relative to zoster 100 100 100 Beta
With PHN 15 9.0 26.5 Beta
With ophthalmic complications 5.3 4.2 6.4 Beta
Breakthrough cases with complications, relative to zoster 1 0 5.0 Beta
GP and outpatient costs, €
Varicella and breakthrough varicella
Age r14 y 35.67869 28.5 42.8 Gamma
Age 414 y 44.41758 35.5 53.3 Gamma
Zoster and breakthrough zoster 98.287 78.6 117.9 Gamma
(continued)
Supplemental Table IV. (continued).
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Supplemental Table VI. (continued).
Parameters in the Model and Values With
Distribution for the PSA
Base
Case Low High
Uncertainty
distribution
No complications
þ PHN 145.79 116.6 174.9 Gamma
þ Ophthalmic complications 154.3564 123.5 185.2 Gamma
Hospitalization
Varicella
Cases hospitalized, %
Age 0–o1 y 1.6116 1.2892 1.9339 Beta
Age 1–o5 y 0.1092 0.0874 0.1311 Beta
Age 5–o15 y 0.0725 0.0580 0.0870 Beta
Age 15–o25 y 0.3286 0.2629 0.3944 Beta
Age 25–o35 y 0.6684 0.5347 0.8021 Beta
Age 35–o45 y 0.9041 0.7233 1.0849 Beta
Age 45–o65 y 3.2082 2.5666 3.8499 Beta
Age Z65 y 3.7902 3.0322 4.5482 Beta
Breakthrough cases hospitalized, %
Age 0–o1 y 0.0161 0.0000 0.0967 Beta
Age 1–o5 y 0.0011 0.0000 0.0066 Beta
Age 5–o15 y 0.0007 0.0000 0.0044 Beta
Age 15–o25 y 0.0033 0.0000 0.0197 Beta
Age 25–o35 y 0.0067 0.0000 0.0401 Beta
Age 35–o45 y 0.0090 0.0000 0.0542 Beta
Age 45–o65 y 0.0321 0.0000 0.1925 Beta
Age Z65 y 0.0379 0.0000 0.2274 Beta
Zoster
Cases hospitalized, %
Age 0–o1 y 0.0000 0.0000 0.0000 Beta
Age 1–o5 y 0.5600 0.4480 0.6720 Beta
Age 5–o15 y 0.6700 0.5360 0.8040 Beta
Age 15–o25 y 1.4450 1.1560 1.7340 Beta
Breakthrough cases hospitalized, %
Age 25–o35 y 0.0000 0.0000 0.0000 Beta
Age 35–o45 y 0.0056 0.0000 0.0336 Beta
Age 45–o65 y 0.0067 0.0000 0.0402 Beta
Age Z65 y 0.0144 0.0000 0.0867 Beta
Hospital costs, €
Varicella and breakthrough varicella 3033.05 2426.44 3639.65 Gamma
Zoster and breakthrough zoster 4319.68 3455.74 5183.61 Gamma
Costs of vaccinations and AEs, €
Per dose of MMRV vaccine 54.00 43.20 64.80 Gamma
Per monovalent varicella vaccine 41.94 33.55 50.33 Gamma
Zoster vaccine 173.00 138.40 207.60 Gamma
Per dose of MMR 15.10 12.08 18.12 Gamma
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Supplemental Table VI. (continued).
Parameters in the Model and Values With
Distribution for the PSA
Base
Case Low High
Uncertainty
distribution
Febrile convulsions
% of vaccine recipients with febrile convulsions 0.05 0.04 0.06 Beta
% with GP visits for febrile convulsions 100 100 100 Beta
% with hospital visits for febrile convulsions 16.00 12.8 19.2 Beta
Costs, mean, €
Per GP visit 22.41 17.93 26.89 Gamma
Per overnight hospital stay 1916.85 1533.48 2300.22 Gamma
Indirect costs
Varicella
Age o18 y
Percentage whose parents lost work time, % 17.00 13.6 20.4 Beta
Workdays lost per case, mean 4.70 4.10 5.20 Gamma
Percentage with alternative child care costs, % 13.00 10.4 15.6 Beta
Age 18–65 y
Percentage who lost work time, % 73.00 67.6 78.4 Beta
Work days lost per case, mean 10.00 8.80 11.10 Gamma
Breakthrough cases with indirect costs, % 1.00% 0.8% 1.2% Beta
Zoster (age 18–65 y)
Percentage who lost work time, % 73.00 67.6 78.4 Beta
Workdays lost per case, mean 16.18 12.95 19.42 Gamma
Breakthrough cases with indirect costs, % 1.00 0.8 1.2 Beta
Cost of alternative childcare, € 77.96 62.37 93.55 Gamma
Cost per workday lost, € 179.56 143.65 215.48 Gamma
QALY loss per case
Varicella
Age 0–o15 y 0.004 0.000 0.006 Beta
Age Z15 y 0.005 0.003 0.010 Beta
Breakthrough varicella (all) 0.001 0.000 0.002 Beta
Zoster
No complications
Age 0–o60 y 0.010 0.006 0.016 Beta
Age 60–o65 y 0.010 0.006 0.016 Beta
Age Z65 y 0.011 0.007 0.017 Beta
With complications
Age 0–o60 y 0.106 0.068 0.162 Beta
Age 60–o65 y 0.106 0.068 0.162 Beta
Age Z65 y 0.144 0.087 0.203 Beta
Breakthrough zoster
No complications
Age 0–o60 y 0.010 0.006 0.014 Beta
Age 60–o65 y 0.010 0.006 0.014 Beta
Age Z65 y 0.0106 0.007 0.016 Beta
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Supplemental Table VI. (continued).
Parameters in the Model and Values With
Distribution for the PSA
Base
Case Low High
Uncertainty
distribution
With complications
Age 0–o60 y 0.098 0.063 0.145 Beta
Age 60–o65 y 0.098 0.063 0.145 Beta
Age Z65 y 0.093 0.060 0.140 Beta
Complications per case, mean
Varicella
Age 0–1 y 0.0629 0.0503 0.0755 Beta
Age 1–o5 y 0.0475 0.0380 0.0570 Beta
Age 5–o10 y 0.0345 0.0276 0.0414 Beta
Age 10–o15 y 0.0353 0.0282 0.0424 Beta
Age 15–o20 y 0.0237 0.0190 0.0284 Beta
Age Z20 y 0.0882 0.0706 0.1058 Beta
Relative propensity for breakthrough disease to cause
complications
0.10 0.00 0.05 Beta
Zoster
Age 0–o60 y 0.0000 0.0000 0.0000 Beta
Age 60–o65 y 0.2318 0.1854 0.2781 Beta
Age Z65 y 0.3881 0.3105 0.4657 Beta
Relative propensity for breakthrough disease to cause
complications
0.01 0.00 0.05 Beta
Deaths due to disease, per case, mean
Varicella
All ages 0.00002 0.000 0.000 Beta
Relative propensity for breakthrough disease to cause
death
0.01 0.000 0.050 Beta
Zoster
Age 0–o45 y 0.0000 0.000 0.000 Beta
Age 45–o50 y 0.000011 0.000 0.000 Beta
Age 50–o55 y 0.000009 0.000 0.000 Beta
Age 55–o60 y 0.000009 0.000 0.000 Beta
Age 60–o65 y 0.000027 0.000 0.000 Beta
Age Z65 y 0.0004 0.000 0.000 Beta
Relative propensity for breakthrough disease to cause
death
0.01 0.000 0.050 Beta
AE ¼ adverse event; GP ¼ general practitioner; MMRV ¼ measles, mumps, rubella, varicella; PHN ¼ post-herpetic neuralgia;
QALY ¼ quality-adjusted life-year.
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